Rationale

We have created a disruptive, plant-based medicine that will change the world, offering

• Accelerated healing of fractures
• Increased bone density
• Reduced inflammation
• Reduced pain
• Restored lost productivity due to incapacitation
• Promotion of mental health following trauma, PTSD, anxiety and post-traumatic depression

In 2019, there were 178 million new fractures, 455 million (428—484) prevalent cases of acute or long-term symptoms of a fracture (an increase of 70·1% (67·5%—72·5%) since 1990. Cited: Lancet Healthy Longevity, 2021 Sep;2(9):e580-e592. NIH: 10.1016/S2666-7568(21)00172-0). (Source)

That is only one example of the potential applications of the product.

We seek to break down walls of traditional development and implementation of medicine, to quantify through science data and track and traceability, and to show medical peers globally the benefits of using M77 when treating fractures, dislocations, crushings and sprains at a cost under 20 to the patient

Business Opportunity

Estimated potential market size: $200 billion annually worldwide.

We invite inquiries from potential partners who understand the need and share our vision.

Our first round may include stock with variable ownership. Our first partner will have first right to purchase any additional shares when offered through any subsidiary company.

Other opportunities may include national or regional distributorships and white-label branding.

Application of Funds

• Acquire equipment to filter and sterilize M77 vials at production scale/volume.
• Additional funding for clinical studies and patent.